Research Topics
| C K CunninghamSummaryAffiliation: SUNY Upstate Medical University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected womenC K Cunningham
Department of Pediatrics, State University of New York, Upstate Medical University, Syracuse, NY 13210, USA
Clin Infect Dis 32:801-7. 2001..Thus, both vaccines were safe and well tolerated in neonates, and there was no evidence of accelerated immunologic decline in HIV-infected infants...- Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3Coleen K Cunningham
Department of Pediatrics, State University of New York Upstate Medical University, Syracuse, Syracuse, NY 13210, USA
J Infect Dis 186:181-8. 2002..The risk of nevirapine resistance should be considered when determining the risks or benefits of intrapartum nevirapine in women receiving antepartum antiretroviral therapy... 
Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USAMarie Louise Newell
Centre of Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, UK
BMC Infect Dis 7:60. 2007....- Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIVKristine L Witt
National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
Environ Mol Mutagen 48:322-9. 2007..These results demonstrate that transplacentalZDV exposure is genotoxic in humans. Long-term monitoring of HIV-uninfected ZDV-exposed infants is recommended to ensure their continued health... - The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316Coleen K Cunningham
Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
J Acquir Immune Defic Syndr 36:800-7. 2004..Race/ethnicity is significant in predicting viral suppression at the time of delivery... - Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316D Heather Watts
National Institute of Child Health and Human Development, Bethesda, MD 20892, USA
Am J Obstet Gynecol 190:506-16. 2004..The purpose of this study was to evaluate rates of maternal toxicity, pregnancy complications, and peripartum morbidity by type and duration of antiretroviral therapy (ART) during pregnancy... - Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine doseMark Mirochnick
Boston University School of Medicine, Boston Medical Center, 91 Concord Street, 6th Floor, Boston, MA 02118, USA
J Acquir Immune Defic Syndr 33:153-6. 2003..To evaluate cord blood and predose nevirapine concentrations in infants exposed to the two-dose intrapartum neonatal nevirapine regimen... - Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trialAlejandro Dorenbaum
Department of Pediatrics, University of California, San Francisco, USA
JAMA 288:189-98. 2002..CONCLUSION: Risk of perinatal HIV transmission was low and no benefit from additional intrapartum/newborn nevirapine was demonstrated when women received prenatal care and antenatal ART, and elective cesarean section was made available... - Newer treatments for HIV in childrenRoss E McKinney
Departmentof Pedicatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
Curr Opin Pediatr 16:76-9. 2004..Several new antiretroviral agents have been introduced into pediatric and adult use. This review will summarize information about these new agents and other recent advances in the care of HIV-infected children... - Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationshipsDolors Soy
Department of Biopharmaceutical Sciences, School of Pharmacy, University of California-San Francisco, San Francisco, Calif, USA
Clin Pharmacol Ther 74:569-80. 2003..CONCLUSIONS: Regarding pharmacokinetics and pharmacodynamics, no statistically significant correlation between exposure measures and viral clearance was observed... - Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected childrenJoseph A Church
Childrens Hospital Los Angeles, Division of Clinical Immunology and Allergy, CA 90027, USA
Pediatr Infect Dis J 23:713-8. 2004..The safety and antiretroviral activity of enfuvirtide treatment of 24 weeks in HIV-1-infected children has been previously documented. Here we present the long term tolerability and safety of enfuvirtide... - Growth as a part of the composite endpoint in paediatric antiretroviral clinical trialsDaniel K Benjamin
Department of Pediatrics, Duke University, Durham, NC, USA
J Antimicrob Chemother 54:701-3. 2004.... - Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infectionJennifer J Kiser
University of Colorado at Denver and Health Sciences Center, Denver, CO, USA
Antimicrob Agents Chemother 52:631-7. 2008..Additional studies of the exposure-response relationships of this regimen in children, adolescents, and adults would advance our knowledge of its pharmacodynamic properties...